Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Lilly’s Humalog Junior KwikPen offers 0.5 unit dose increments in prefilled, disposable device – a win for highly insulin sensitive users
The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins
Amalgam Rx receives FDA clearance for basal insulin dosing app, iSage Rx; available with a prescription to adjust Lantus, Levemir, Toujeo, Tresiba, and Basaglar
How to get cheaper drugs, find discount programs, get free care in clinical trials, and more
Novo Nordisk’s once-weekly injectable GLP-1 for type 2 diabetes recommended for approval, given strong A1c reduction and weight loss
Includes insulin dose advisor software; plus, a new Novo Nordisk connected Echo insulin pen to debut in Europe later this year
An FDA advisory panel voted 17-2 to expand the drug label for type 2 diabetes drug Victoza to reflect a 13% reduction in overall heart risk and 22% reduction in heart-...
How I avoid highs, prevent lows, and stop blood sugar frustration during exercise
Easy-to-use Bydureon pen cuts down on the hassle of once-weekly injections by offering convenient mixing, a hidden needle, and more​
A basal insulin and GLP-1 agonist combo becomes available in the US and receives approval in Europe
Information about diabetes supplies for those hit by the storms and for those who can help them
First trial next month, launch expected in 2-3 years; Dexcom CGM included; a big commitment to diabetes tech innovation from an insulin company
Seeking participants with type 2 diabetes to investigate the effects of semaglutide on heart health
Full results of DEVOTE study presented at ADA 2017 show that basal insulin Tresiba reduces risk of severe hypoglycemia by 40% (by 53% overnight), in addition to being...
FDA Approves New GLP-1 Label on Victoza to show that the medicine makes hearts healthier!
What’s new in smart pens and caps for capturing injection doses? Plus, two cool new health apps with built-in artificial intelligence
Cash-pay strips with good accuracy and co-pay programs to save money
CANVAS study presented at ADA 2017 highlights heart and kidney protection for type 2 diabetes drug Invokana, and questions persist over an increased risk of amputations
A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide
Novo Nordisk’s newest insulin receives EMA approval; expected to launch in the first half of 2017

Pages